LOINC
Version 2.69

2007-3Cancer Ag 15-3 [Presence] in Serum or PlasmaActive

Part Descriptions

LP15461-4   Cancer Ag 15-3
CA 15-3 is a tumor marker for breast cancer. It is derived from MUC1. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, CA 15-3

LP15461-4   Cancer Ag 15-3
Cancer antigen 15-3 (CA 15-3) is a mucin molecule and blood tumor marker used to gauge the response to treatment of invasive breast cancer. CA 15-3 is encoded by the MUC1 gene and is a transmembrane glycoprotein. CA 15-3 may contribute to the growth of breast tumors by preventing tumor cell cytolysis by cytotoxic T-cells or lymphokine-activated cells. It may also block the proliferation of T-cells by causing apoptosis. In addition, CA 15-3 has been found to be expressed over the entire cell in malignant breast tissue while normal breast tissue expresses CA 15-3 only on the apical side of the glanudular epithelial cells. The presence of CA 15-3 is not unique to patients with breast cancer, but can also be found in patients with lung, colorectal, ovarian, and pancreatic cancers. Patients with primary tumors tend to have lower levels of CA 15-3, though the average concentration and percentage of patients goes up as the tumor stage or size of the tumor increases. While only a small number of recurrences of local or regional tumors result in an increased CA 15-3 level, over 70% of patients with remote metastasis have much higher CA 15-3 levels. [PMID: 10505206] Source: Regenstrief LOINC

Fully-Specified Name

Component
Cancer Ag 15-3
Property
PrThr
Time
Pt
System
Ser/Plas
Scale
Ord
Method

Additional Names

Short Name
Cancer Ag15-3 SerPl Ql
Display Name
Cancer Ag 15-3 Ql
Consumer Name Alpha
Cancer Ag 15-3, Blood

Basic Attributes

Class
CHEM
Type
Laboratory
First Released
Version 1.0
Last Updated
Version 2.56
Change Reason
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.
Order vs. Observation
Both

Language Variants Get Info

zh-CNChinese (China)
癌抗原 15-3:存在情况或阈值:时间点:血清/血浆:序数型:
nl-NLDutch (Netherlands)
CA15.3:aanwezigheid:moment:serum of plasma:ordinaal:
et-EEEstonian (Estonia)
Kasvajaantigeen CA 15-3:PrThr:Pt:S/P:Ord:
fr-BEFrench (Belgium)
Ag carbohydraté 15-3:PrThr:Temps ponctuel:Sérum/Plasma:Ordinal:
fr-CAFrench (Canada)
Ag carbohydraté 15-3:Présence-Seuil:Temps ponctuel:Sérum/Plasma:Ordinal:
fr-FRFrench (France)
Carbohydrate antigène 15.3:Présence/Seuil:Ponctuel:Sérum/Plasma:Qualitatif:
el-GRGreek (Greece)
Καρκινικό αντιγόνο 15-3:PrThr:Χρονική στιγμή:Ορός/Πλάσμα:Τακτική:
it-ITItalian (Italy)
Cancro, Ag 15-3:PrThr:Pt:Siero/Plasma:Ord:
ko-KRKorean (Korea, Republic of)
암 항원 15-3:임의농도:검사시점:혈청/혈장:순위척도:
pt-BRPortuguese (Brazil)
Câncer Ag 15-3:ACnc:Pt:Sor/Plas:Ord:
ru-RURussian (Russian Federation)
Раковый Аг 15-3:PrThr:ТчкВрм:Сыв/Плаз:Пор:
es-ARSpanish (Argentina)
antígeno cáncer 15-3:concentración arbitraria:punto en el tiempo:suero/plasma:ordinal:
es-ESSpanish (Spain)
Antígeno CA 15-3:PrThr:Punto temporal:Suero o Plasma:Ord:
tr-TRTurkish (Turkey)
Kanser Ag 15-3:MevcEşik:Zmlı:Ser/Plaz:Srl:

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=2007-3